Personal information

United Kingdom

Activities

Employment (1)

The Christie NHS Foundation Trust: Manchester, GB

Specialty Registrar Doctor (Medical Oncology)
Employment
Source: Self-asserted source
Roya Behrouzi

Education and qualifications (6)

University of Manchester: Manchester, GB

2023-09-01 to 2024-10-01 | MSc Precision Medicine (Distinction)
Education
Source: Self-asserted source
Roya Behrouzi

Royal College of Physicians: London, GB

2022-09-06 | Specialty Certificate Examination (SCE) (Medical Oncology)
Education
Source: Self-asserted source
Roya Behrouzi

Edge Hill University: Omskirk, GB

2022-03-01 | Postgraduate Workplace-Based Medical Education
Education
Source: Self-asserted source
Roya Behrouzi

Royal College of Physicians: London, London, GB

2019-03-01 | MRCP(UK)
Education
Source: Self-asserted source
Roya Behrouzi

The University of Manchester: Manchester, Greater Manchester, GB

2016-07-01 | MBChB(Hons) Medicine
Education
Source: Self-asserted source
Roya Behrouzi

The University of Manchester: Manchester, Greater Manchester, GB

2011-07-01 | BSc(Hons) Pharmacology
Education
Source: Self-asserted source
Roya Behrouzi

Works (24)

Cell-free and extrachromosomal DNA profiling of small cell lung cancer.

Trends in molecular medicine
2024-09 | Journal article
Contributors: Behrouzi R; Clipson A; Simpson KL; Blackhall F; Rothwell DG; Dive C; Mouliere F
Source: Self-asserted source
Roya Behrouzi via Europe PubMed Central

Dimethyl fumarate in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial.

Nature communications
2024-01 | Journal article
Contributors: RECOVERY Collaborative Group; Horby PW; Peto L; Staplin N; Campbell M; Pessoa-Amorim G; Mafham M; Emberson JR; Stewart R; Prudon B et al.
Source: Self-asserted source
Roya Behrouzi via Europe PubMed Central

Immunomodulatory therapy in children with paediatric inflammatory multisystem syndrome temporally associated with SARS-CoV-2 (PIMS-TS, MIS-C; RECOVERY): a randomised, controlled, open-label, platform trial.

The Lancet. Child & adolescent health
2024-01 | Journal article
Contributors: RECOVERY Collaborative Group
Source: Self-asserted source
Roya Behrouzi via Europe PubMed Central

CDK4/6 inhibitors versus weekly paclitaxel for treatment of ER+/HER2- advanced breast cancer with impending or established visceral crisis

Breast Cancer Research and Treatment
2023-11 | Journal article
Contributors: Roya Behrouzi; Anne C. Armstrong; Sacha J. Howell
Source: check_circle
Crossref

Empagliflozin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial.

The lancet. Diabetes & endocrinology
2023-10 | Journal article
Contributors: RECOVERY Collaborative Group
Source: Self-asserted source
Roya Behrouzi via Europe PubMed Central

Immunotherapy-related adverse events in real-world patients with advanced non-small cell lung cancer on chemoimmunotherapy: a Spinnaker study sub-analysis.

Frontiers in oncology
2023-05 | Journal article
Contributors: Anpalakhan S; Huddar P; Behrouzi R; Signori A; Cave J; Comins C; Cortellini A; Addeo A; Escriu C; McKenzie H et al.
Source: Self-asserted source
Roya Behrouzi via Europe PubMed Central

Higher dose corticosteroids in patients admitted to hospital with COVID-19 who are hypoxic but not requiring ventilatory support (RECOVERY): a randomised, controlled, open-label, platform trial.

Lancet (London, England)
2023-04 | Journal article
Contributors: RECOVERY Collaborative Group. Electronic address: recoverytrial@ndph.ox.ac.uk; RECOVERY Collaborative Group
Source: Self-asserted source
Roya Behrouzi via Europe PubMed Central

Immunotherapy-related adverse events (irAEs) in real world patients with advanced non-small cell lung cancer (aNSCLC) on chemoimmunotherapy: a Spinnaker study sub-analysis

Lung Cancer
2023-04 | Journal article
Part of ISSN: 0169-5002
Contributors: Shobana Anpalakhan; Prerana Huddar; Roya Behrouzi; Alessio Signori; Judith Cave; Charles Comins; Alessio Cortellini; Alfredo Addeo; Carles Escriu; Hayley McKenzie et al.
Source: Self-asserted source
Roya Behrouzi via Crossref Metadata Search

The Effects of GCSF Primary Prophylaxis on Survival Outcomes and Toxicity in Patients with Advanced Non-Small Cell Lung Cancer on First-Line Chemoimmunotherapy: A Sub-Analysis of the Spinnaker Study

International Journal of Molecular Sciences
2023-01-16 | Journal article
Contributors: Shobana Anpalakhan; Prerana Huddar; Roya Behrouzi; Alessio Signori; Judith Cave; Charles Comins; Alessio Cortellini; Alfredo Addeo; Carles Escriu; Hayley McKenzie et al.
Source: check_circle
Crossref
grade
Preferred source (of 3)‎

Baricitinib in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial and updated meta-analysis.

Lancet (London, England)
2022-07 | Journal article
Contributors: RECOVERY Collaborative Group
Source: Self-asserted source
Roya Behrouzi via Europe PubMed Central

Casirivimab and imdevimab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial.

Lancet (London, England)
2022-02 | Journal article
Contributors: RECOVERY Collaborative Group
Source: Self-asserted source
Roya Behrouzi via Europe PubMed Central

Azithromycin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial

The Lancet
2021 | Journal article
EID:

2-s2.0-85100615475

Part of ISSN: 1474547X 01406736
Contributors: Abaleke, E.; Abbas, M.; Abbasi, S.; Abbott, A.; Abdelaziz, A.; Abdelbadiee, S.; Abdelfattah, M.; Abdul, B.; Abdul Rasheed, A.; Abdul-Kadir, R. et al.
Source: Self-asserted source
Roya Behrouzi via Scopus - Elsevier

Convalescent plasma in patients admitted to hospital with COVID-19 (RECOVERY): a randomised controlled, open-label, platform trial

The Lancet
2021 | Journal article
EID:

2-s2.0-85106644551

Part of ISSN: 1474547X 01406736
Contributors: Abani, O.; Abbas, A.; Abbas, F.; Abbas, M.; Abbasi, S.; Abbass, H.; Abbott, A.; Abdallah, N.; Abdelaziz, A.; Abdelfattah, M. et al.
Source: Self-asserted source
Roya Behrouzi via Scopus - Elsevier

HE4 as a biomarker for endometrial cancer

Cancers
2021 | Journal article
EID:

2-s2.0-85115432751

Part of ISSN: 20726694
Contributors: Behrouzi, R.; Barr, C.E.; Crosbie, E.J.
Source: Self-asserted source
Roya Behrouzi via Scopus - Elsevier
grade
Preferred source (of 2)‎

Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial

The Lancet
2021 | Journal article
EID:

2-s2.0-85104923041

Part of ISSN: 1474547X 01406736
Contributors: Abani, O.; Abbas, A.; Abbas, F.; Abbas, M.; Abbasi, S.; Abbass, H.; Abbott, A.; Abdallah, N.; Abdelaziz, A.; Abdelfattah, M. et al.
Source: Self-asserted source
Roya Behrouzi via Scopus - Elsevier

Aspirin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial.

Lancet (London, England)
2021-11 | Journal article
Contributors: RECOVERY Collaborative Group
Source: Self-asserted source
Roya Behrouzi via Europe PubMed Central
grade
Preferred source (of 2)‎

327P Predictors of progression-free survival in patients with metastatic breast cancer receiving palbociclib with letrozole

Annals of Oncology
2021-09 | Journal article
Part of ISSN: 0923-7534
Source: Self-asserted source
Roya Behrouzi

Baseline serum HE4 but not tissue HE4 expression predicts response to the levonorgestrel-releasing intrauterine system in atypical hyperplasia and early stage endometrial cancer

Cancers
2020 | Journal article
EID:

2-s2.0-85078460345

Part of ISSN: 20726694
Contributors: Behrouzi, R.; Ryan, N.A.J.; Barr, C.E.; Derbyshire, A.E.; Wan, Y.L.; Maskell, Z.; Stocking, K.; Pemberton, P.W.; Bolton, J.; McVey, R.J. et al.
Source: Self-asserted source
Roya Behrouzi via Scopus - Elsevier
grade
Preferred source (of 2)‎

P2.17-02 Survival in Performance Status 3 Non-Small Cell Lung Cancer Patients Receiving Radical Radiotherapy

Journal of Thoracic Oncology
2019-10 | Journal article
Part of ISSN: 1556-0864
Source: Self-asserted source
Roya Behrouzi

Medication Safety Group clinician updates: a novel teaching programme to bridge the gap between the prescriber and the trust

Future Healthcare Journal
2019-03 | Journal article
Part of ISSN: 2514-6645
Part of ISSN: 2514-6653
Source: Self-asserted source
Roya Behrouzi

Diagnosis and management of cerebral venous thrombosis

Clinical Medicine, Journal of the Royal College of Physicians of London
2018 | Journal article
EID:

2-s2.0-85042623996

Contributors: Behrouzi, R.; Punter, M.
Source: Self-asserted source
Roya Behrouzi via Scopus - Elsevier

Irradiation decreases the neuroendocrine biomarker pro-opiomelanocortin in small cell lung cancer cells in vitro and in vivo

PLoS ONE
2016 | Journal article
EID:

2-s2.0-84959387542

Contributors: Meredith, S.L.; Bryant, J.L.; Babur, M.; Riddell, P.W.; Behrouzi, R.; Williams, K.J.; White, A.
Source: Self-asserted source
Roya Behrouzi via Scopus - Elsevier

Pathological tau deposition in Motor Neurone Disease and frontotemporal lobar degeneration associated with TDP-43 proteinopathy

Acta neuropathologica communications
2016 | Journal article
EID:

2-s2.0-84994602651

Contributors: Behrouzi, R.; Liu, X.; Wu, D.; Robinson, A.C.; Tanaguchi-Watanabe, S.; Rollinson, S.; Shi, J.; Tian, J.; Hamdalla, H.H.; Ealing, J. et al.
Source: Self-asserted source
Roya Behrouzi via Scopus - Elsevier

143. A New Evidence-Based Information Leaflet for Systemic Lupus Erythematosus Patients Providing Guidance about the Use of Medications During Pregnancy and Breastfeeding

Rheumatology
2015-04-20 | Journal article
Part of ISSN: 1462-0332
Source: Self-asserted source
Roya Behrouzi